Cargando…

820 Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b

Detalles Bibliográficos
Autores principales:	Brunetto, Maurizia, Rana, Khurram, Taliani, Gloria, Lawitz, Eric, Hézode, Christophe, Marcellin, Patrick, Serfaty, Lawrence, Cohen, David, Srinivasan, Subasree
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781668/ http://dx.doi.org/10.1093/ofid/ofu052.528

Ejemplares similares

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
por: Foster, Graham R., et al.
Publicado: (2016)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

822 Effect of Steady State Daclatasvir Plus Asunaprevir on the Single Dose Pharmacokinetics of the P-glycoprotein Substrate Digoxin in Healthy Adult Subjects
por: Garimella, Tushar, et al.
Publicado: (2014)

645 Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women
por: Lo Re, Vincent, et al.
Publicado: (2014)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

603 Transmission of Hepatitis C Virus (HCV) from a Deceased Organ Donor at Increased Risk of HCV infection with Negative Nucleic Acid Test Screening at the Time of Organ Donation
por: Theodoropoulos, Nicole, et al.
Publicado: (2014)

1147 Factors Associated with Spontaneous Resolution of HCV Infection in Untreated Individuals, Philadelphia
por: Kuncio, Danica, et al.
Publicado: (2014)

Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile
por: Vargas, Constanza L., et al.
Publicado: (2015)

1562 The Influence of Co-infection with HCV on CD4 and B-cell Reconstitution in Human Immunodeficiency Virus (HIV)-infected Patients
por: Abers, Michael S., et al.
Publicado: (2014)

1135 High rates of self-reported alcohol use in HIV/HCV co-infected and HIV mono-infected patients in a Southeastern U.S. Cohort
por: Wallender, Erika, et al.
Publicado: (2014)

Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens
por: Reddy, K. Rajender, et al.
Publicado: (2017)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015)

610 Incidence of Potentially Inappropriate Dual Antimicrobial Therapy in U.S. hospitals
por: Schultz, Leslie, et al.
Publicado: (2014)

346 Longterm carriage of Ciprofloxacin-Resistant E. Coli Isolates among Nursing Home (NH) Residents
por: Ismail, Miriam, et al.
Publicado: (2014)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
por: Silva, Giovanni Faria, et al.
Publicado: (2013)

784 Acute respiratory infections and Streptococcus pneumoniae Carriage
por: De Lastours, Victoire, et al.
Publicado: (2014)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
por: Sacco, Rodolfo, et al.
Publicado: (2020)

1145 2009 H1N1 Compared to Post-pandemic H1N1 Influenza Among Pediatric Inpatients
por: Rao, Suchitra, et al.
Publicado: (2014)

1057 Factors Associated with Influenza A (H1N1)pdm09 (pH1N1) Vaccine Failure among Children Aged 5-17 Years
por: Mclean, Huong, et al.
Publicado: (2014)

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin
por: Toyoda, Hidenori, et al.
Publicado: (2012)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
por: Labarga, P, et al.
Publicado: (2010)

1154 Host and Pathogen Genetics Modulate HSV-1 Severity
por: Ramchandani, Meena, et al.
Publicado: (2014)

953 Using Statistical-Derived Incubation Period Estimation in an Outbreak Investigation of Influenza A (H1N1) pdm09 in Operating Room Staff
por: Maharom, Pasri, et al.
Publicado: (2014)

1141 2013-2014 Resurgence of 2009 Influenza A (H1N1) Infection among Adults: Has the Epidemiology and Clinical Severity of Disease Changed?
por: Arnold, John, et al.
Publicado: (2014)

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
por: Hézode, Christophe, et al.
Publicado: (2017)

1651 Role of Metronidazole vs Vancomycin as Initial Therapy in Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs non-NAP1 Disease
por: Dubrovskaya, Yanina, et al.
Publicado: (2014)

535 Effectiveness of Seasonal Influenza Vaccines against Influenza A(H1N1)pdm09 Illness during Three Influenza Seasons, US Flu VE Network
por: Flannery, Brendan, et al.
Publicado: (2014)

351 NDM-1-producing Escherichia coli Isolated from a Case Patient's Environment
por: Buser, Genevieve L., et al.
Publicado: (2014)

1468 Detection of High CSF Levels of (1 → 3)-Beta-D-Glucan in Cryptococcal Meningitis
por: Rhein, Joshua, et al.
Publicado: (2014)

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
por: Domagalski, Krzysztof, et al.
Publicado: (2013)

Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin
por: Reau, N, et al.
Publicado: (2012)

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
por: Leroy, Vincent, et al.
Publicado: (2016)

1703 Delta-like 1 ligand (DLL) measurement in cerebrospinal fluid for detection of Mycobacterium tuberculosis meningitis
por: Bahr, Nathan, et al.
Publicado: (2014)

1333 Therapeutic HSV-2 vaccine (GEN003) results in durable reduction in genital lesions at 1 year
por: Wald, Anna, et al.
Publicado: (2014)

540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis
por: Brinson, Cynthia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h8sqm9janj823hjihfu02vs98p